Document is current
Any future updates will be listed below
-
Authors
Leone, Julieta
Freedman, Rachel A.
Lin, Nancy U.
Tolaney, Sara M.
Vallejo, Carlos T.
Leone, Bernardo A.
Winer, Eric P.
Leone, José Pablo https://orcid.org/0000-0002-8537-652X
- License Information
-
More Information
Article History
Received: 22 January 2021
Accepted: 5 March 2021
First Online: 26 March 2021
Compliance with ethical standards
:
: JPL received research funding from Kazia Therapeutics and Merck. RAF has institutional research funding from Puma Biotechnology. SMT receives institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odonate, Sanofi, and Nektar. SMT has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Paxman, Athenex, Oncopep, Daiichi-Sankyo, G1 Therapeutics, Silverback Therapeutics, Kyowa Kirin Pharmaceuticals, AbbVie, Sanofi, Seattle Genetics, Celldex, Bristol-Myers Squibb, and Nanostring. EPW consultant honoraria from Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Novartis, Seattle Genetics, Syros; scientific advisory board for Leap; institutional research support from Genentech/Roche. NUL receives institutional research funding from Genentech, Merck, Seattle Genetics, and Pfizer and has served as an advisor/consultant to Seattle Genetics, AstraZeneca, Daiichi-Sankyo, Denali Therapeutics, and the California Institute for Regenerative Medicine. All other authors have declared no conflicts of interest.
: The study was exempted from Institutional Review Board review because we utilized de-identified, previously collected, publicly available data.
: The study was exempted from Institutional Review Board review because we utilized de-identified, previously collected, publicly available data.
: Not applicable.
: Not applicable.
